These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25883884)

  • 1. F-18 fluorodeoxyglucose positron emission tomography for differential diagnosis of pancreatic tumors.
    Yoshioka M; Uchinami H; Watanabe G; Sato T; Shibata S; Kume M; Ishiyama K; Takahashi S; Hashimoto M; Yamamoto Y
    Springerplus; 2015; 4():154. PubMed ID: 25883884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas.
    Tomimaru Y; Takeda Y; Tatsumi M; Kim T; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Kitagawa T; Nagano H; Umeshita K; Wakasa K; Doki Y; Mori M
    Oncol Rep; 2010 Sep; 24(3):613-20. PubMed ID: 20664965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of
    Regenet N; Sauvanet A; Muscari F; Meunier B; Mariette C; Adham M; Moutardier V; Delpero JR; Regimbeau JM; Pessaux P; Paye F; Sa Cunha A; Ansquer C
    J Visc Surg; 2020 Oct; 157(5):387-394. PubMed ID: 32005594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules.
    Takanami K; Hiraide T; Tsuda M; Nakamura Y; Kaneta T; Takase K; Fukuda H; Takahashi S
    Ann Nucl Med; 2011 Aug; 25(7):501-10. PubMed ID: 21537945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
    Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
    Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of F-18 fluorodeoxyglucose positron emission tomography with dual-phase imaging to identify intraductal papillary mucinous neoplasm.
    Saito M; Ishihara T; Tada M; Tsuyuguchi T; Mikata R; Sakai Y; Tawada K; Sugiyama H; Kurosawa J; Otsuka M; Uchida Y; Uchiyama K; Miyazaki M; Yokosuka O
    Clin Gastroenterol Hepatol; 2013 Feb; 11(2):181-6. PubMed ID: 23142206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the performance of visual estimation and standard uptake value of F-18 fluorodeoxyglucose positron emission tomography/computed tomography for detecting malignancy in pancreatic tumors other than invasive ductal carcinoma.
    Otomi Y; Otsuka H; Terazawa K; Nose H; Kubo M; Matsuzaki K; Ikushima H; Bando Y; Harada M
    J Med Invest; 2014; 61(1-2):171-9. PubMed ID: 24705763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study.
    Sperti C; Pasquali C; Decet G; Chierichetti F; Liessi G; Pedrazzoli S
    J Gastrointest Surg; 2005 Jan; 9(1):22-8; discussion 28-9. PubMed ID: 15623441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of F-18 FDG PET/CT with optimal cut-offs of maximum standardized uptake value according to size for diagnosis of regional lymph node metastasis in patients with rectal cancer.
    Bae SU; Won KS; Song BI; Jeong WK; Baek SK; Kim HW
    Cancer Imaging; 2018 Sep; 18(1):32. PubMed ID: 30217167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of positron emission tomography (PET)/contrast-enhanced computed tomography (CE-CT) in discriminating between malignant and benign intraductal papillary mucinous neoplasms (IPMNs).
    Ohta K; Tanada M; Sugawara Y; Teramoto N; Iguchi H
    Pancreatology; 2017; 17(6):911-919. PubMed ID: 29033011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Searching for indicators of malignancy in pancreatic intraductal papillary mucinous neoplasms: the value of 18FDG-PET confirmed.
    Baiocchi GL; Bertagna F; Gheza F; Grazioli L; Calanducci D; Giubbini R; Portolani N; Giulini SM
    Ann Surg Oncol; 2012 Oct; 19(11):3574-80. PubMed ID: 22752369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The utility of F-18 FDG PET/CT in the evaluation of pancreatic intraductal papillary mucinous neoplasm.
    Hong HS; Yun M; Cho A; Choi JY; Kim MJ; Kim KW; Choi YJ; Lee JD
    Clin Nucl Med; 2010 Oct; 35(10):776-9. PubMed ID: 20838285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.
    Nakamoto Y; Higashi T; Sakahara H; Tamaki N; Kogire M; Doi R; Hosotani R; Imamura M; Konishi J
    Cancer; 2000 Dec; 89(12):2547-54. PubMed ID: 11135214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors.
    Tomimaru Y; Eguchi H; Tatsumi M; Kim T; Hama N; Wada H; Kawamoto K; Kobayashi S; Morii E; Mori M; Doki Y; Nagano H
    Surgery; 2015 Feb; 157(2):269-76. PubMed ID: 25311263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic usefulness of FDG PET for pancreatic mass lesions.
    Koyama K; Okamura T; Kawabe J; Nakata B; Chung KH; Ochi H; Yamada R
    Ann Nucl Med; 2001 Jun; 15(3):217-24. PubMed ID: 11545191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.